Open Access Articles- Top Results for Cefixime


Systematic (IUPAC) name
1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Clinical data
Trade names Suprax
AHFS/ monograph
MedlinePlus a690007
  • B
  • (Prescription only)
Oral capsule/suspension
Pharmacokinetic data
Bioavailability 40% to 50%
Protein binding Approximately 60%
Half-life Variable
Average 3 to 4 hours
Excretion Renal and biliary
79350-37-1 7pxY
PubChem CID 5362065
DrugBank DB00671 7pxY
ChemSpider 4514923 7pxY
UNII 97I1C92E55 7pxY
KEGG D00258 7pxY
ChEBI CHEBI:472657 7pxY
Chemical data
Formula C16H15N5O7S2
453.452 g/mol
 14pxY (what is this?)  (verify)

Cefixime is an antibiotic useful for the treatment of a number of bacterial infections. It is a third generation cephalosporin developed by Wyeth Pharmaceuticals. It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system.[1]

Medical uses

Cefixime treats infections of the:
Ear: Otitis caused by Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pyogenes.
Sinuses: Sinusitis.
Throat: Tonsillitis, pharyngitis caused by Streptococcus pyogenes.
Chest and lungs: Bronchitis, pneumonia caused by Streptococcus pneumoniae and Haemophilus influenzae.

It is also used to treat typhoid fever

Spectrum of bacterial susceptibility

Cefixime is a broad spectrum cephalosporin antibiotic and is commonly used to treat bacterial infections of the ear, urinary tract, and upper respiratory tract. The following represents MIC susceptibility data for a few medically significant microorganisms:[2]

  • Escherichia coli: 0.015 µg/mL - 4 µg/mL
  • Haemophilus influenzae: ≤0.004 µg/mL - >4 µg/mL
  • Proteus mirabilis: ≤0.008 µg/mL - 0.06 µg/mL

Mechanism of action

The bactericidal action of Cefixime is due to the inhibition of cell wall synthesis. It binds to one of the penicillin binding proteins (PBPs) which inhibits the final transpeptidation step of the peptidoglycan synthesis in the bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.

Only 40-50% is absorbed from the GI tract (oral). Rate may be decreased if taken with food. Absorption from oral suspensions than tablet is more.

It has high concentrations in bile and urine. It can cross the placenta and its protein binding capacity is 65%.

It is always better to perform appropriate cultures and susceptibility studies to determine the causative organism and its sensitivity to cefixime.


Cefixime is contraindicated in patients with known sensitivity or allergies to cephalosporin class of antibiotics. As Cefixime is a third generation cephalosporin, it is not contraindicated for patients with a true penicillin allergy.[3]

Adverse effects

Adverse drug reactions include diarrhea, dyspepsia, nausea and vomiting. Hypersensitivity reactions like skin rashes, urticaria and Stevens-Johnson syndrome have been reported. There is no specific antidote for Cefixime overdosage. Gastric lavage may performed. Dialysis will not remove Cefixime in significant quantities.

Drug Interactions

  • Alcohol - No major interaction has been observed between cefixime and alcohol.[4]


It was sold under the trade name Suprax 125 in the USA until 2003 when it was taken off the market by drug manufacturer Wyeth after its patent expired.

Trade Names

Trade names include:

  • Ofex (Delta Pharma Ltd. Bangladesh)
  • Taxim-O (Alkem Laboratories Limited, India)
  • C-3 (Astra Biopharmaceuticals Ltd. Bangladesh)


  1. ^ "WHO Model List of EssentialMedicines" (PDF). World Health Organization. October 2013. Retrieved 22 April 2014. 
  2. ^
  3. ^
  4. ^